Showing results (111-120 of 123) with videos related to

Sort By:
Pageof 13
Rheumatology (Oxford, England)|June 28, 2020
Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort studyRebekka Lund Hansen, Tanja Schoedt Jørgensen, Lene Dreyer, et al.
Seminars in Arthritis and Rheumatism|October 18, 2017
A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiativePil Højgaard, Louise Klokker, Ana-Maria Orbai, et al.
The Journal of Rheumatology|March 2, 2021
Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid ArthritisKaterina Chatzidionysiou, Merete Lund Hetland, Thomas Frisell, et al.
Annals of the Rheumatic Diseases|August 21, 2017
Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative projectLouise K Mercer, Anne C Regierer, Xavier Mariette, et al.
Rheumatology (Oxford, England)|December 3, 2015
Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registryBente Glintborg, Pil Højgaard, Merete Lund Hetland, et al.
Oncology|October 11, 2013
Non-lymphoma hematological malignancies in systemic lupus erythematosusMary Lu, Sasha Bernatsky, Rosalind Ramsey-Goldman, et al.
Clinical Epidemiology|December 15, 2017
Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient RegistryElse Helene Ibfelt, Jan Sørensen, Dorte V Jensen, et al.
The Journal of Rheumatology|December 3, 2016
Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO RegistryBente Glintborg, Inge J Sørensen, Mikkel Østergaard, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|November 6, 2025
Autoantibody-defined subsets of patients with systemic lupus erythematosus associate with clinical manifestations, NCF2, and HLA DR3-DQ2 genotypesHenrik Christian Bidstrup Leffers, Anne Troldborg, Martin Andersen, et al.
Annals of the Rheumatic Diseases|December 10, 2023
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)Romain Aymon, Denis Mongin, Sytske Anne Bergstra, et al.
Pageof 13